Dr. Nicole Frahm

For the Media

Dr. Nicole Frahm

Dr. Nicole Frahm is an associate member of Fred Hutchinson Cancer Research Center's Vaccine and Infectious Disease Division.  She oversees the HIV Vaccine Trial Network’s laboratory program at Fred Hutch in Seattle.  The lab focuses on the cellular immune response to HIV infection. A major focus of the lab program is to identify correlates of protection (CoP), which are immune markers that indicate protection from infection. RV144, the first HIV vaccine trial to show protection, allowed the ability to propose CoPs.

Resources for more information

  • Overview of Nicole Frahm's Research
    The study of people’s immune responses to HIV in order to inform vaccine design.
  • Nicole Frahm – Brief Curriculum Vitae
    Appointments, affiliations and researcher interests.
  • Vaccine and Infectious Disease Division
    VIDD’s research aims at preventing, diagnosing, treating and understanding infectious diseases. There is a wide range of research topics under investigation across the fields of biology, medicine and public health. VIDD is organized into four research programs that integrate multiple research interests.
  • HIV Vaccine Trials Network (HVTN)
    The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV/AIDS. The HVTN conducts all phases of clinical trials, from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy.

FOR THE MEDIA

Hutch Team

For more information or to arrange an interview, please contact Fred Hutch at (206) 667-2210 or email our media relations team.


 

Photos / Graphics / Video

Download

Download photos and view video of Nicole Frahm.

Related Stories


At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.